You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Addressing Access to PCSK9 Inhibitors: Tips and Tools For Practicing Clinicians

  • Authors:

    Seth J. Baum, MD; Joyce L. Ross, MSN, CNRP; Christie M. Ballantyne, MD; Charles "Kurt" Mahan, PharmD, Phc

  • CME / ABIM MOC / CE Released: 9/20/2018
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/20/2019
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, primary care providers, diabetologists, endocrinologists, nurses, nurse practitioners, and pharmacists.

The goal of this activity is to improve access to proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • FDA- and guideline-recommended patient selection criteria for PCSK9 inhibitor therapy
  • Have greater competence related to
    • Team-based strategies to improve access to PCSK9 inhibitor therapy


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Seth J. Baum, MD

    President, American Society for Preventive Cardiology
    Founder, Chief Medical Officer
    Excel Medical Clinical Trials, LLC
    Clinical Affiliate Professor of Biomedical Science
    Florida Atlantic University
    Charles E. Schmidt College of Medicine
    Medical Director, Women's Preventive Cardiology
    Christine E. Lynn Women's Health & Wellness Institute
    Boca Raton Regional Hospital
    Boca Raton, Florida

    Disclosures

    Disclosure: Seth J. Baum, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Akcea Therapeutics; Amgen Inc.; Novo Nordisk; Regeneron Pharmaceuticals, Inc.; Sanofi
    Served as a speaker or a member of a speakers bureau for: Akcea Therapeutics; Amgen Inc.; Aralez Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Novo Nordisk; Regeneron Pharmaceuticals, Inc.

    Dr Baum does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Baum does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Joyce L. Ross, MSN, RN-C, CRNP, CS

    Diplomate Accreditation Council for Clinical Lipidology
    Past President, National Lipid Association
    Past President Preventive Cardiovascular Nurses Association
    Philadelphia, Pennsylvania

    Disclosures

    Disclosure: Joyce L. Ross, MSN, CNRP, CS, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Sanofi
    Served as a speaker or a member of a speakers bureau for: Amarin Corporation plc; Amgen Inc.; Kaneka Americas Holding, Inc.; Kowa Company Ltd.; Regeneron Pharmaceuticals, Inc.; Sanofi

    Ms Ross does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Ms Ross does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Christie M. Ballantyne, MD

    Professor of Medicine
    Chief of Cardiology and Cardiovascular Research
    Baylor College of Medicine
    Director, Center for Cardiovascular Disease Prevention
    Houston Methodist DeBakey Heart and Vascular Center
    Houston, Texas

    Disclosures

    Disclosure: Christie M. Ballantyne, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Abbott; Akcea Therapeutics; Amarin Corporation plc; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Denka Seiken Co., Ltd.; Esperion Therapeutics, Inc.; Gilead Sciences, Inc.; Lilly; Matinas Biopharma Holdings, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi
    Received grants for clinical research from: Abbott; Akcea Therapeutics; Amarin Corporation plc; Amgen Inc.; Esperion Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi

    Dr Ballantyne does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Ballantyne does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Charles (Kurt) Mahan PharmD, PhC

    Clinical Assistant Professor of Pharmacy
    Cardiac Critical Care Pharmacist
    Presbyterian Healthcare Services University of New Mexico College of Pharmacy
    Albuquerque, New Mexico

    Disclosures

    Disclosure: Charles "Kurt" Mahan, PharmD, PhC, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Janssen Pharmaceuticals; Portola Pharmaceuticals, Inc.
    Served as a speaker or a member of a speakers bureau for: Bristol-Myers Squibb Company; Janssen Pharmaceuticals; Pfizer Inc.; Portola Pharmaceuticals, Inc.

    Mr Mahan does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Mr Mahan does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Joy P. Marko, MS, APN-C, CCMEP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

  • Kalanethee Paul-Pletzer, PhD

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Kalanethee Paul-Pletzer, PhD, has disclosed no relevant financial relationships.

CME Reviewer / Nurse Planner

  • Amy Bernard, MS, BSN, RN-BC, CHCP

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, CHCP, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50  AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number JA0007105-0000-18-185-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Addressing Access to PCSK9 Inhibitors: Tips and Tools For Practicing Clinicians

Authors: Seth J. Baum, MD; Joyce L. Ross, MSN, CNRP; Christie M. Ballantyne, MD; Charles "Kurt" Mahan, PharmD, PhcFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC / CE Released: 9/20/2018

Valid for credit through: 9/20/2019

processing....

  • Print